PMID: 2499553Jun 15, 1989Paper

The cost-effectiveness of breast cancer screening

International Journal of Cancer. Journal International Du Cancer
P J van der MaasJ H Hendriks

Abstract

The costs and effects of different invitation schedules of breast cancer screening are compared. The effect estimates are based on trials from the USA, Sweden and the Netherlands. The cost estimates use registration data, file studies and organization charts. The calculations were performed with the MISCAN computer simulation package, which is developed especially for the evaluation of mass screening programmes. Screening women of 50-70 years at 2-yearly intervals is a relatively cost-effective schedule. In a real population, it will reduce breast cancer mortality by 12%. Screening of women under 50 is probably far less cost-effective. Screening induces a considerable shift towards breast-conserving therapy. Although a 12% mortality reduction may seem low, in absolute numbers this represents more than the total mortality from, e.g., cervical cancer. Moreover, cost per death prevented or per life-year saved is much lower than for most other medical interventions for which cost-effectiveness ratios are known, screening for cervical cancer included.

References

Oct 15, 1986·International Journal of Cancer. Journal International Du Cancer·D PalliG Maltoni
Oct 15, 1988·BMJ : British Medical Journal·I AnderssonB Sigfússon
Aug 3, 1985·British Medical Journal·A Williams
Sep 10, 1988·BMJ : British Medical Journal·E G Knox
Aug 28, 1986·The New England Journal of Medicine·H O AdamiB Stone
Jul 10, 1982·Journal of Health Economics·H S GravelleJ Chamberlain
Feb 9, 1986·Journal of Health Economics·G W Torrance

❮ Previous
Next ❯

Citations

Feb 1, 1992·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·J E TillE M Meslin
Jan 1, 1990·Social Science & Medicine·M A KoopmanschapJ K Habbema
Jan 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C WilliamsS Wait
Sep 6, 2000·Social Science & Medicine·L W NiessenF F Rutten
Aug 1, 1997·Social Science & Medicine·E Elsinga, F F Rutten
Mar 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J McCannN Day
Dec 28, 1999·Critical Reviews in Oncology/hematology·D Gyrd-Hansen
Dec 28, 1999·Critical Reviews in Oncology/hematology·K Perez-NiddamS Charvet-Protat
Oct 25, 2002·Journal of Women's Health & Gender-based Medicine·Lisa Gale SuterJoann G Elmore
Apr 28, 1999·Journal of the National Cancer Institute·R H Secker-WalkerA S Detsky
Jun 8, 2006·Journal of the National Cancer Institute·Natasha K StoutDennis G Fryback
Feb 24, 2001·Journal of Clinical Gastroenterology·D Provenzale, J Onken
Aug 1, 1994·Journal of Epidemiology and Community Health·S F HurleyL Quang
May 10, 2008·Breast Cancer Research : BCR·Harald Weedon-FekjaerSteinar Tretli
Aug 12, 2009·PharmacoEconomics·Natasha K StoutG Scott Gazelle
Mar 28, 2008·Scandinavian Journal of Gastroenterology·Maiken Thyregod JørgensenOve B Schaffalitzky De Muckadell
Oct 1, 2001·Expert Review of Pharmacoeconomics & Outcomes Research·A HarrisF R Drummond
Mar 15, 1990·International Journal of Cancer. Journal International Du Cancer·M A KoopmanschapK T Lubbe
Oct 21, 1991·International Journal of Cancer. Journal International Du Cancer·H J de KoningP J van der Maas
Aug 15, 1990·International Journal of Cancer. Journal International Du Cancer·G J van OortmarssenP J van der Maas
Dec 18, 2001·Health Economics·D Gyrd-Hansen, J Søgaard
Mar 23, 2011·Obstetrics and Gynecology Clinics of North America·Stephen Feig
Sep 28, 2010·Radiologic Clinics of North America·Stephen Feig
Apr 20, 2010·The Breast : Official Journal of the European Society of Mastology·Gail S LebovicStephen A Feig
Jul 1, 2004·Alimentary Pharmacology & Therapeutics·S DuBois, K V Kowdley
Jun 6, 2003·European Journal of Cancer Care·P ArveuxP Schaffer
Dec 1, 1994·Urology·R M Benoit, M J Naslund
Jan 1, 1991·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M Goddard, M Drummond
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·B M van IneveldP J van der Maas
Jan 9, 2003·Gastrointestinal Endoscopy·Stephen J RulyakTeresa A Brentnall
Apr 25, 2015·The Breast : Official Journal of the European Society of Mastology·Rositsa G Koleva-KolarovaGeertruida H De Bock
Apr 1, 1992·Cancer·A I Mushlin, L Fintor
Jun 22, 1999·International Journal of Psychiatry in Medicine·A C LeonD V Sheehan
Jan 11, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Amy B KnudsenG Scott Gazelle
Jun 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeanne S MandelblattMarianne Fahs
Nov 10, 2007·São Paulo Medical Journal = Revista Paulista De Medicina·Vivian MilaniJacob Szejnfeld

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.